SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologic s, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc.

Global CDMO utilizes Seattle facility’s mammalian biologics expertise to support late-stage clinical trials for leading international biopharma organization AGC Biologics’ Seattle facility has ...

SEATTLE & HEIDELBERG, Germany, July 29, 2025--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine ...

AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality. The collaboration will focus on ...

As part of its global expansion strategy, AGC Biologics is increasing manufacturing capacity at its Copenhagen, Denmark facility. AGC Biologics is a global leader in clinical and commercial ...

SEATTLE & MILAN--(BUSINESS WIRE)-- AGC Biologics, your friendly CDMO expert, today announced a partnership with Quell Therapeutics (“Quell”), a clinical-stage biotechnology company pioneering ...

SEATTLE--(BUSINESS WIRE)--AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a Lentiviral vector (LVV) expansion to its ...

SEATTLE, March 10, 2025--(BUSINESS WIRE)--AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the company won two awards from ...

AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the ...

Manufacturing excellence positions Seattle site as premier destination for mammalian and microbial biologic production in thriving Pacific Northwest life sciences hub SEATTLE--(BUSINESS WIRE)-- AGC ...